Broadstreet is pleased to be presenting several posters at this year’s virtual ISPOR Europe meeting.
USE OF REAL-WORLD EVIDENCE TO EVALUATE INFLIXIMAB BIOSIMILARS: A SCOPING REVIEW
Antoinette Cheung,1 Lauren Powell,1 Tissa Rahim,1 Scott Emerson,2 Karissa Johnston1
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada; 2St. Paul’s Hospital, Vancouver, BC, Canada
This work includes a scoping review that looks at the availability of real-world evidence describing infliximab biosimilars compared to infliximab originator for the treatment of inflammatory, rheumatic, and autoimmune diseases. Through our review, we identified evidence primarily from Europe on this topic, while finding studies from North America or Asia were lacking. The work also highlights the lack of real-world evidence describing health resource utilization associated with infliximab biosimilars.
TWO SENSITIZATION METHODS TO ENHANCE PARTICIPANT ENGAGEMENT DURING THE CONDUCT OF AN ONLINE DISCRETE CHOICE EXPERIMENT: A CASE STUDY
Mickle AT,1 Popoff E,1 Corepal R,1 Lozano-Ortega G1
1Broadstreet Health Economics and Outcomes Research, Vancouver BC, Canada
We also present our findings of a case study looking at enhancing participant engagement in an online discrete choice experiment (DCE). Two different methods for sensitizing DCE respondents to the importance of respondent engagement were tested and we found that in-person phone calls prior to conducting self-led, internet based DCEs may increase participant engagement.
PREFERENCES FOR HEMOPHILIA TREATMENTS IN CANADA: A DISCRETE CHOICE EXPERIMENT (DCE)
KM Johnston,1 JM Stoffman,2 AT Mickle,1 S Olatunde,3 RJ Klaassen,4 D Diles3
1Broadstreet Health Economics and Outcomes Research, Vancouver; 2University of Manitoba, Winnipeg; 3Hoffmann-La Roche Limited, Canada; 4Children’s Hospital of Eastern Ontario Research Institute, Ottawa
Finally, in collaborations with our colleagues at Roche Canada, we are presenting the findings of a DCE aiming to elicit preferences for features of hemophilia A treatments from a Canadian societal perspective. The results suggest preference for treatments which have favorable efficacy and safety profiles, subcutaneous over IV administration, and require less-frequent prophylactic treatments.
We hope this is the final year that this meeting has to be virtual and look forward to seeing all our ISPOR Europe friends and colleagues in person next year!